Who
Iain D. Dukes
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Traws Pharma; Director, Iovance Biotherapeutics; CEO and Chairman, Lomond Therapeutics Holdings; Director, ImageneBio; Chairman, Theseus Pharmaceuticals.
In numbers
- Trades disclosed
- 47
- Buys
- 3
- Sells
- 0
- Bought
- $458K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 16 Aug 2016
- Last trade
- 9 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jul 2026filed 14 Jul 2026 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,000 at $0.00 | filing |
| 9 Jul 2026filed 14 Jul 2026 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,632 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,632 at $0.00 | filing |
| 8 Mar 2026filed 10 Mar 2026 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —231,336 at $0.00 | filing |
| 8 Mar 2026filed 10 Mar 2026 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —231,336 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —147,771 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | TRAW Traws PharmaBiotechnology | SEC FORM 4 Code A | —36,943 at $0.00 | filing |
| 12 Oct 2025filed 15 Oct 2025 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,839 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,092 at $0.00 | filing |
| 1 Nov 2024filed 5 Nov 2024 | Lomond Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —2,096,667 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,607 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,520 at $0.00 | filing |
| 1 Apr 2024filed 7 Aug 2024 | TRAW Traws PharmaBiotechnology | SEC FORM 4 Code A | —67,500 | filing |
| 1 Apr 2024filed 3 Apr 2024 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,802,890 | filing |
| 1 Apr 2024filed 3 Apr 2024 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —194.62 | filing |
| 1 Apr 2024filed 3 Apr 2024 | TRAW Traws Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,801.11 | filing |
| 1 Apr 2024filed 3 Apr 2024 | TRAW Traws PharmaBiotechnology | SEC FORM 4 Code A | —66,687 | filing |
| 1 Apr 2024filed 3 Apr 2024 | TRAW Traws PharmaBiotechnology | SEC FORM 4 Code A | —67,550 | filing |
| 1 Apr 2024filed 3 Apr 2024 | TRAW Traws PharmaBiotechnology | SEC FORM 4 Code A | —1,645,100 | filing |
News
Undercovered Stocks: Hess Midstream, Iovance Biotherapeutics, Netlist, And MoreIOVA · seekingalpha.com · 19 Oct 2026Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)IOVA · tickerreport.com · 15 Oct 2026Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $11.00IOVA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Iain D. Dukes; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.